Eupraxia Pharmaceuticals Insider Trading
TSX EPRX
3
All Trades
3
Significant
0
Notable
0
Clusters
0
Repeat
Filter:
↓ CSV↓ Excel↓ PDF
Previous1Next
| Company | Insider | Title | Date | Shares | Price | Value | Balance | Increase | Signal |
|---|---|---|---|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals | ██████ | ████████ | ██-███-26 | ███,███ | $█.██ | $███,███ | ███,███ | ██% | ████████ |
| Eupraxia Pharmaceuticals | ██████ | ████████ | ██-███-26 | ███,███ | $█.██ | $███,███ | ███,███ | ██% | ████████ |
| Eupraxia Pharmaceuticals | ██████ | ████████ | ██-███-26 | ███,███ | $█.██ | $███,███ | ███,███ | ██% | ████████ |
| Company | Insider | Title | Date | Shares | Price | Value | Balance | Increase | Signal |
|---|---|---|---|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals | Pimstone, Simon | Chairman | 27-Mar-26 | 12,000 | $9.46 | $113,505 | 44,678 | 37% | Significant |
| Eupraxia Pharmaceuticals | Brennan, Paul | Chief Development Officer | 24-Nov-25 | 16,300 | $8.83 | $143,875 | 43,500 | 60% | Significant |
| Eupraxia Pharmaceuticals | Freedman, Joseph | Director | 16-Jun-25 | 23,400 | $5.35 | $125,220 | 45,400 | 106% | Significant |
Stock Chart
Related Companies to Explore
Company Info
Eupraxia Pharmaceuticals Inc. is a Canadian clinical-stage biopharmaceutical company focused on developing locally-acting microsphere-based drug formulations for the treatment of musculoskeletal pain and inflammation. The company’s lead program EP-104IAR is being developed for the treatment of knee osteoarthritis pain, offering an extended-release formulation designed for single-injection quarterly dosing. Headquartered in Victoria, British Columbia, Eupraxia is advancing its pipeline through clinical trials. Listed on the Toronto Stock Exchange under the ticker EPRX.